BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NicVax: Preliminary Phase II data

Preliminary data from a double-blind, Dutch Phase II trial in 558 patients showed that NicVax plus Chantix varenicline missed the primary endpoint of improving abstinence rate at 12 months as measured from week 9 through week 52 using self-reported cigarette consumption and exhaled carbon dioxide vs. placebo plus Chantix. Last year,...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >